zum Inhalt
Header Image

02: Cancer research and cancer care – Construction and reality

Seminar / Seminar
in englischer Sprache

Overall, cancer is one of the most frequent causes of death, and the impact of this disease on society is enormous. Fortunately, cancer research is one of the most dynamic fields in medical research, and significant resources, both public and industrial, are invested into the field. Tremendous progress has been made in the diagnosis and treatment of many cancers, and there is rarely another field in medical research where breakthrough technology – mostly from molecular biology – has been translated to actual benefit as rapidly as in cancer medicine.

Despite significant recent improvements in treatment modalities and outcome several problem fields in cancer research persist or unfold: How can we further improve the results of early detection and treatment? Is there cure for cancer? And if so – what are the implications of this vision for society? How are we measuring patient benefit in a holistic sense? Since cost of cancer research is increasing exponentially, what is the actual value of further progress for society?

In addition, research progress is not the only issue in the field of modern cancer medicine: Improving cancer care in a multidimensional sense of the word is considered an equally important subject, with several unresolved questions: What are the psychological and social consequences of this disease even if hope can be offered by medicine? How to cope with the socioeconomic fall-out for patients affected and their families? How to provide equal access to modern medical achievements in the existing diversity of health care systems throughout Europe? What are the implications of an integrated view of cancer care on society?

In this seminar, these main questions and related aspects of the subject will be discussed, and potential answers developed together with participants and internationally renowned guest speakers from several fields in order to provide a multi-dimensional perspective on one of the most exciting fields in modern medicine.

Professor, Department of Oncology-Pathology, Karolinska Institutet, Stockholm
President, Colon Cancer Support Group, Vienna
Professor and Deputy Director, Department of Surgery, Medical University of Vienna Chair
Professor of Medical Oncology; Director, Breakthrough Breast Cancer Research Unit, Paterson Institute for Cancer Research, University of Manchester Chair

Ph.D. Jonas BERGH

Professor, Department of Oncology-Pathology, Karolinska Institutet, Stockholm

1973-1979 Medical School, Umeå and Uppsala University, Sweden (MD)
1980-1982 Internship (Internal Medicine, Anaesthesiology, Surgery, Psychiatry, GP) Uppsala University Hospital, license to practice medicine in Sweden
1982 PhD in Pathology/Tumour biology, University of Uppsala
1979-1980 and 1982-1988 Clinical training and Education in Pathology and Oncology
1986 Board certified in Pathology in Sweden; Board certified in Oncology, includes Medical Oncology and Radiotherapy
1986-1998 Associate Professor in Experimental Oncology, Uppsala University
1988 Licence to practice medicine, specialist in Clinical Oncology UK 2/9, 2009
1988-1998 Senior registrar, assistant consultant and consultant, Dept of Oncology, University Hospital, Uppsala, Sweden
since 1999 Consultant, Karolinska University Hospital, Radiumhemmet (20% from October 2009)
2000-2008 Professor of clinical and molecular oncology, Karolinska Institutet
since 2008 Professor of Oncology (Mimi Althainz´ donation, the first chair in radiotherapy, later transferred to oncology in Sweden), Karolinska Institutet
2007-2009 Scientific Director Karolinska Oncology and Medical Director for the Clinical Trial Unit
since 2009 Chairman for the Oncology-Haematology expert group (LÄKSAK), Stockholm County Council
Professor of Breast Oncology, Paterson Institute/Manchester University
Honorary consultant at the Breast Unit, Medical Oncology Unit, Christie Hospital and Director Manchester Breast Centre


President, Colon Cancer Support Group, Vienna

  Ausbildung zur MTA (Ord. Prof. Dr. Thurnher, Prof. Dr. Olbert)
seit 1999 Key Account Manager, Magazin "Society" sowie PR und Eventorganisation
seit 2006 Leitung, Selbsthilfegruppe Darmkrebs
  Herausgeberin, Magazin "Forum Darmkrebs"
  Veranstalterin der "Tage der Darmgesundheit"

Dr. Michael GNANT

Professor and Deputy Director, Department of Surgery, Medical University of Vienna

1982-1988 Medizinstudium, Universität Wien
1986 Auslandsstudium Universität München, Deutschland
1988 Promotion zum Dr. med. univ.
1988-1989 Koordinator, Abteilung f. Transplantation (1. Chirurgische Universitätsklinik)
1990-1994 Universitätsassistent, 1. Chirurgische Universitätsklinik. Ausbildung in Allgemeinchirurgie mit Rotation in Gefäßchirurgie, Unfallchirurgie, Intensivmedizin, Gerichtliche Medizin. Ausbildung in Medizinischer und experimenteller Onkologie an der Universitätsklinik für Innere Medizin. Universitätslektor an der medizinischen Fakultät
1994 Facharzt für Chirurgie
1995 Ernennung zum Oberarzt der Universitätsklinik für Chirurgie
seit 1996 Leiter, Arbeitsgruppe Mammakarzinom
Leiter, Arbeitsgruppe Experimentelle Chirurgische Onkologie
1997-1998 Auslandsaufenthalt am National Cancer Institute / NIH, Bethesda, USA / Surgery Branch (Chief: Dr. Steven Rosenberg)
1999 Rückkehr nach Wien
2000 Lehrbefugnis im Fach Chirurgie; Verleihung des Titels Außerordentlicher Universitätsprofessor
Leiter, Arbeitsgruppe Pankreaskarzinom
Station 21D/Klinik für Chirurgie: bettenführender Oberarzt
2003 Reihung als "primo et unico loco" durch Berufungskommission/Fakultät für die neugeschaffene Professur für Chirurgisch-exp. Onkologie der Medizinischen Fakultät der Universität Wien
2004 Berufung als Professor für Chirurgisch-experimentelle Onkologie an die Medizinische Universität Wien


Professor of Medical Oncology; Director, Breakthrough Breast Cancer Research Unit, Paterson Institute for Cancer Research, University of Manchester

 Anthony Howell is Professor of Medical Oncology and is the Director of the Breakthrough Breast Cancer Research Unit, University of Manchester. Formerly he was Chairman of the UKCCCR - United Kingdom Coordinating Committee on Cancer Research, the British Breast Group and the Manchester Breast Centre, was the Research and Development Director of The Christie NHS Foundation Trust and the Cancer Research Network. His interests are the endocrine therapy and biology of the breast and breast cancer with a particular interest in prevention. He has published over 500 papers mainly in these areas. He is also principal investigator on several clinical trials, including those developing 'pure' antioestrogens.


Timetable einblenden
kategorie: Alle Plenary Seminar
Genre : Alle Panel Seminar